Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Authors: Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, Ann S. LaCasce, John F. Gerecitano, John P. Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi‐Lin Chiu, Yue Cui, Todd Busman, Steven W. Elmore, Saul H. Rosenberg, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse - The Lancet 2010 cited by 853